Galera Therapeutics, Inc.
General ticker "GRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6M (TTM average)
Galera Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -15.4%.
Estimated limits based on current volatility of 6.0%: low 0.02$, high 0.03$
Factors to consider:
- Earnings expected soon, date: 2025-12-11 bmo
- Total employees count: 31 as of 2022
- Top business risk factors: Economic downturns and volatility, Market competition, Regulatory and compliance, Cybersecurity threats, Intellectual property risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.02$, 0.16$]
- 2025-12-31 to 2026-12-31 estimated range: [0.05$, 0.25$]
Financial Metrics affecting the GRTX estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -723.77 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -4.48 < Investing cash flow per share per price, % of -2.74
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term GRTX quotes
Long-term GRTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $51.23MM | $49.26MM | $20.16MM |
| Operating Income | $-51.23MM | $-49.26MM | $-20.16MM |
| Non-Operating Income | $-11.07MM | $-9.82MM | $1.00MM |
| Interest Expense | $11.57MM | $11.41MM | $0.00MM |
| R&D Expense | $31.01MM | $24.11MM | $3.15MM |
| Income(Loss) | $-62.29MM | $-59.08MM | $-19.16MM |
| Taxes | $0.07MM | $0.00MM | $-0.20MM |
| Profit(Loss)* | $-62.22MM | $-59.08MM | $-18.96MM |
| Stockholders Equity | $-109.18MM | $-131.19MM | $-143.67MM |
| Assets | $44.04MM | $26.14MM | $10.10MM |
| Operating Cash Flow | $-43.43MM | $-44.85MM | $-12.14MM |
| Capital expenditure | $0.03MM | $0.06MM | $0.00MM |
| Investing Cash Flow | $23.99MM | $27.29MM | $-0.05MM |
| Financing Cash Flow | $3.89MM | $31.50MM | $2.22MM |
| Earnings Per Share** | $-2.30 | $-1.33 | $-0.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.